AIM ImmunoTech Inc. (AIM): Total Liabilities
$15.56M
As of 2025-12-31
$4.99M
As of 2026-06-30
+97.5%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.56M | +56.7% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $9.93M | +8.6% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $9.15M | +352.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $2.02M | n/a | 2024-04-01, Balance as of period end |
| No annual figure between 2014-12-31 and 2022-12-31. | |||
| 2014-12-31 | $4.44M | +72.7% | 2015-03-19, Balance as of period end |
| 2013-12-31 | $2.57M | -80.2% | 2015-03-19, Balance as of period end |
| 2012-12-31 | $13.00M | +134.3% | 2014-03-14, Balance as of period end |
| 2011-12-31 | $5.55M | -3.2% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $5.73M | n/a | 2012-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $15.56M | +56.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $8.83M | +18.2% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $2.89M | +120.8% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $45.63M | -3.1% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
| Prokidney Corp. (PROK) | 2025-12-31 | $34.78M | -11.8% |
Compare AIM, VIVS, INMB, ZIVO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗